Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Company Financials: Orthopaedics and Spine

RTI Biologics
$114.1MM, +9%

     Spine $39.7MM, +17%
     Sports Medicine $48.1MM, +7%
     Bone Graft Substitutes/General Orthopaedic (BGS/GO) $26.2MM, +4%

4Q11 orthopaedic revenue: $28.8MM, +5%
     Spine $8.6MM, -8%
     Sports Medicine $13.2MM, +8%
     BGS/GO $6.9MM, +22%

  • Full year spine growth buoyed by mid-year stocking orders, favorable comps
  • Spine business is 70%-80% Medtronic
  • Expects sports med procedure increase and continued pricing pressure
  • BGS/GO sales supported by U.S. sales growth, uptick in commercial distributor revenue
  • BGS/GO direct distribution +47% year over year
  • Expects to begin human implantation of Multipotent Adult Progenitor Cell (MAPC) technology-based implants during 2012
  • Initiating large primate study for xenograft tendon to support premarketing approval application pathway in U.S.

Seikagaku (for fiscal 3Q11, ended 12/31/11)
¥7,225MM (~US $94.3MM), flat
(Performance details pertain to preceding 9 months)

  • U.S. sales of Supartz rose as impact of tightening of reimbursements ran its course, increase in sales at specialty pharmacies where Supartz can be sold at comparatively high prices
  • U.S. sales rose due to increased volume
  • Export sales to China continue to rise, sales to Europe increased

Smith & Nephew
$3,251MM, +3%
Orthopaedics $2,312MM, +2%* (U.S. $1,204MM, +2%, Europe $622MM, -1%; Rest of World $486MM, +7%)

  • Hips $705MM, -1%
  • Knees $869MM, +5%
  • Trauma $457MM, +3%
  • Clinical Therapies $237MM, +6%

Endoscopy $939MM, +6% (U.S. $363MM, +3%; Europe $294MM, +5%; Rest of World $282MM, +12%)

  • Arthroscopy $806MM, +7% (Resection +4%)
  • Visualization $108MM, -7%

4Q11 orthopaedic revenue: $835MM, +2%
Orthopaedics $586MM, flat* (U.S. $311MM, flat; Europe $149MM, -7%; Rest of World $126MM, +10%)

  • Hips -2% (U.S. -5%, ex-U.S. -1%)
  • Knees +2% (U.S. flat, ex-U.S. +4%)
  • Trauma -2% (U.S. +1%, ex-U.S. -6%)
  • Clinical Therapies $61MM, +8%

Endoscopy $249MM, +7% (U.S. $97MM, +3%; Europe $79MM, +8%; Rest of World $73MM, +10%)

  • Arthroscopy $MM, +9% (Repair +12%, Resection +5%)

*Revenue excludes Wound Management.